×

Kraig Biocraft Laboratories' Succeeds in Doubling Its Production of Monster Silk(TM)

Kraig Bancraft Logo

LANSING, Mich., July 9, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced that its Monster Silk™ production program has successfully doubled in size, achieving another major milestone in the Company's spider silk commercialization process.

"Earlier this year, we set ambitious goals for the growth of our Company and for the production of genetically engineered spider silk," said Company Founder and CEO, Kim K Thompson. "Since then, we have expanded our productive capacity in order to make that growth a reality. The current production run is by far the largest in the Company's history. The doubling of production is an important milestone in the commercialization of spider silk and is affirmation of the success of our production plan and commercialization strategy," stated Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com

Source:Kraig Biocraft Laboratories, Inc